연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
535. 8-hydroxydeoxyguanosine suppresses NO production and COX-2 activity via Rac1/STATs signaling in LPS-induced brain microglia.
Kim HS, Ye SK, Cho IH, Jung JE, Kim DH, Choi S, Kim YS, Park CG, Kim TY, Lee JW, Chung MH.
Free Radic Biol Med. 2006; 41(9):1392-403.
Link
534. Integrin signaling and cell spreading mediated by phorbol 12-myristate 13-acetate treatment.
Lee MS, Kim YB, Lee SY, Kim JG, Kim SH, Ye SK, Lee JW.
Journal of Cellular Biochemistry 2006,99;88-95
Link
533. Epigenetic regulation of Integrin-Linked Kinase expression depending on adhesion of gastric carcinoma cells. American Journal of Physiology-Cell Physiology.
Kim YB, Lee SY, Ye SK, Lee JW.
2006,September 20,2006.doi:10.1152/ajpcell.00169.2006
Link
531. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Lee KW, Kim JH, Park JH, Kim HP, Song SH, Kim SG, Kim TY, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ.
Anticancer Res. 2006 Sep-Oct;26(5A):3429-38.
Link
530. High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Lee KH, Lee SH, Kim DW, Kang WJ, Chung JK, Im SA, Kim TY, Kim YW, Bang YJ, Heo DS.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4232-6.
Link
529. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK.
Leuk Lymphoma. 2006 Jul;47(7):1274-82.
Link
528. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Lee KH, Han SW, Hwang PG, Oh DY, Kim DW, Chung DH, Im SA, Kim TY, Heo DS, Bang YJ.
Jpn J Clin Oncol. 2006 Jun;36(6):344-50.
Link
527. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ.
Clin Cancer Res. 2006 Apr 15;12(8):2538-44.
Link
526. Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome.
Park SR, Baek JY, Kim DW, Im SA, Kim TY, Bang YJ, Kim NK, Jeon YK, Kim CW, Heo DS.
J Korean Med Sci. 2006 Aug;21(4):633-8.
Link